Drug profile · INN
guanfacine hydrochloride
INTUNIV PARTIAL CHANGE APPROVAL
guanfacine hydrochloride (INTUNIV PARTIAL CHANGE APPROVAL) is a adrenergic receptor alpha-2 agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — guanfacine hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 15
- Data quality
- 0.89
Quick answer
guanfacine hydrochloride (INTUNIV PARTIAL CHANGE APPROVAL) is a adrenergic receptor alpha-2 agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Adrenergic receptor alpha-2 agonist
Primary target: Adrenergic receptor alpha-2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is guanfacine hydrochloride?
guanfacine hydrochloride (INTUNIV PARTIAL CHANGE APPROVAL) is a adrenergic receptor alpha-2 agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for guanfacine hydrochloride?
INTUNIV PARTIAL CHANGE APPROVAL is a marketed brand name for guanfacine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of guanfacine hydrochloride?
guanfacine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.